Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Amazon Explores AI Content Marketplace With Media Publishers 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
NEWARK, Calif., Feb. 20, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2017 financial results on Tuesday, February 27, 2018, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-844-839-0046 |
| International Dial-in Number: | 1-857-270-6032 |
| Conference ID: | 2157887 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]
Daniel Peisert
VP, Business Development
[email protected]
